prikaz prve stranice dokumenta The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status
  Download
PDF 756.69 KB
Scientific paper - Original scientific paper
The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status
Journal of Clinical Medicine, 13 (2024), 24; 7717. https://doi.org/10.3390/jcm13247717
Fodor Duric, Ljiljana; Belčić, Velimir; Oberiter Korbar, Anja; Ćurković, Sanja; Vujičić, Božidar; Gulin, Tonko; Muslim, Jelena; Gulin, Matko; Grgurević, Mladen; Catic Cuti, Edina

Cite this document

Fodor Duric, Lj., Belčić, V., Oberiter Korbar, A., Ćurković, S., Vujičić, B., Gulin, T. ... Catic Cuti, E. (2024). The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status. Journal of Clinical Medicine, 13. (24). doi: 10.3390/jcm13247717

Fodor Duric, Ljiljana, et al. "The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status." Journal of Clinical Medicine, vol. 13, no. 24, 2024. https://doi.org/10.3390/jcm13247717

Fodor Duric, Ljiljana, Velimir Belčić, Anja Oberiter Korbar, Sanja Ćurković, Božidar Vujičić, Tonko Gulin, Jelena Muslim, Matko Gulin, Mladen Grgurević and Edina Catic Cuti. "The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status." Journal of Clinical Medicine 13, no. 24 (2024). https://doi.org/10.3390/jcm13247717

Fodor Duric, Lj., et al. (2024) 'The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status', Journal of Clinical Medicine, 13(24). doi: 10.3390/jcm13247717

Fodor Duric Lj, Belčić V, Oberiter Korbar A, Ćurković S, Vujičić B, Gulin T, and sur.. The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status. Journal of Clinical Medicine [Internet]. 2024 December 18 [cited 2025 January 14];13(24). doi: 10.3390/jcm13247717

Lj. Fodor Duric, et al., "The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status", Journal of Clinical Medicine, vol. 13, no. 24, December 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:148388. [Accessed: 14 January 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status
AuthorLjiljana Fodor Duric
AuthorVelimir Belčić
AuthorAnja Oberiter Korbar
AuthorSanja Ćurković
AuthorBožidar Vujičić
AuthorTonko Gulin
AuthorJelena Muslim
AuthorMatko Gulin
AuthorMladen Grgurević
AuthorEdina Catic Cuti
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Urology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: Metabolic-associated fatty liver disease (MAFLD) is a spectrum of liver diseases linked to insulin resistance (IR), type 2 diabetes, and metabolic disorders. IR accelerates fat accumulation in the liver, worsening MAFLD. Regular physical activity and weight loss can improve liver function, reduce fat, and lower cardiovascular risk. This study examines the role of sex hormone-binding globulin (SHBG) in MAFLD, focusing on its potential as a biomarker and its relationship with insulin resistance. Methods: The study included 98 male patients (ages 30–55) with MAFLD, identified through systematic examinations, and 74 healthy male controls. All participants underwent abdominal ultrasound and blood tests after fasting, assessing markers such as glucose, liver enzymes (AST, ALT, γGT), lipids (cholesterol, triglycerides), insulin, SHBG, estradiol, and testosterone. SHBG levels were analyzed in relation to body mass index (BMI) and age. Results: A significant association was found between low SHBG levels and the presence of fatty liver. Individuals with MAFLD had lower SHBG levels compared to controls. BMI and age were key factors influencing SHBG, with higher BMI linked to lower SHBG in younger men, while SHBG remained stable in older individuals regardless of BMI. Conclusion: SHBG may serve as a valuable biomarker for early detection and risk assessment of MAFLD. The complex relationship between SHBG, BMI, and age highlights the importance of considering both hormonal and metabolic factors when assessing fatty liver risk. Our findings support the need for comprehensive metabolic evaluations in clinical practice.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleJournal of Clinical Medicine
Numberingvol. 13, no. 24, 7717
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm13247717
URN:NBNurn:nbn:hr:184:148388
Publication2024-12-18
Document URLhttps://www.mdpi.com/2077-0383/13/24/7717
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-12-23 07:51:11